Urinalysis laboratory services

PKI-402 is a potent dual pan-PI3K/mTOR inhibitor targeting PI3Kα/β/γ/δ and mTOR with IC50 of 2 nM/7 nM/16 nM/14 nM and 3 nM, respectively: also potent to PI3Kα mutants E545K and H1047R.

PKI-402 is a potent dual pan-PI3K/mTOR inhibitor targeting PI3Kα/β/γ/δ and mTOR with IC50 of 2 nM/7 nM/16 nM/14 nM and 3 nM, respectively: also potent to PI3Kα mutants E545K and H1047R.

PKI-402 is a potent dual pan-PI3K/mTOR inhibitor targeting PI3Kα/β/γ/δ and mTOR with IC50 of 2 nM/7 nM/16 nM/14 nM and 3 nM, respectively: also potent to PI3Kα mutants E545K and H1047R.

PKI-402 is a potent dual pan-PI3K/mTOR inhibitor targeting PI3Kα/β/γ/δ and mTOR with IC50 of 2 nM/7 nM/16 nM/14 nM and 3 nM, respectively: also potent to PI3Kα mutants E545K and H1047R.

ApplicationML 141 has been used:to inhibit CDC42 GTPase in human immortalized gingival epithelial (HIGE) cellsas inhibitors of Rho kinase to study the role of small Rho GTPases on localization of peripheral nucleias actin regulator inhibitor, to

Selective TREK channel activator.

Selective TREK channel activator.

Selective TREK channel activator.

Selective TREK channel activator.

Selective TREK channel activator.

Selective TREK channel activator.

Selective TREK channel activator.